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BACKGROUND: Commonly used estimated glomerular
filtration rate (eGFR) equations include a Black race
modifier (BRM) that was incorporated during equation
derivation. Race is a social construct, and a poorly characterized variable that is applied inconsistently in clinical
settings. The BRM results in higher eGFR for any creatinine concentration, implying fundamental differences
in creatinine production or excretion in Black individuals compared to other populations. Equations without
inclusion of the BRM have the potential to detect kidney disease earlier in patients at the greatest risk of
chronic kidney disease (CKD), but also has the potential
to over-diagnose CKD or impact downstream clinical
interventions. The purpose of this study was to use an
evidence-based approach to systematically evaluate the
literature relevant to the performance of the eGFR equations with and without the BRM and to examine the
clinical impact of the use or removal.

PubMed and Embase databases were searched
for studies comparing measured GFR to eGFR in racially
diverse adult populations using the Modification of Diet
in Renal Disease or the 2009-Chronic Kidney Disease
Epidemiology Collaboration-creatinine equations based on
standardized creatinine measurements. Additionally, we
searched for studies comparing clinical use of eGFR calculated with and without the BRM. Here, 8632 unique
publications were identified; an additional 3 studies
were added post hoc. In total, 96 studies were subjected
to further analysis and 44 studies were used to make a
final assessment.
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There is limited published evidence to support the use of a BRM in eGFR equations.

SUMMARY:

Introduction
Estimated glomerular filtration rate (eGFR) equations
provide important clinical information on renal function;
these equations are commonly used in the diagnosis and
stratification of chronic kidney disease (CKD), drug
and dose selection, and safety assessments for radiologic
and oncologic interventions (1). Estimation equations utilize the combination of an endogenous filtration marker
with additional surrogates for non-GFR determinants that
may impact marker concentrations (2).
Worldwide, creatinine is the most frequently used
filtration marker in eGFR calculations, and although its
use is widely accepted, its concentration is affected by
nonglomerular factors such as variability in tubular secretion and extra-renal variables such as diet, muscle
mass, and use of certain drugs. Within the USA, the 2
most commonly used estimation equations for adults
are the 4-variable Modification of Diet in Renal Disease
(4v-MDRD) and the 2009-Chronic Kidney Disease
Epidemiology Collaboration-creatinine (CKD-EPICr)
calculations (3, 4). In practice, eGFR is commonly
reported in conjunction with blood creatinine, and implementation of these equations has been fairly straightforward, as neither equation requires an individual’s
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evaluate the applicability of the BRM in eGFR calculations, as well as the influence of the modifier
on clinical outcomes, particularly in North American
settings, which frequently use the BRM.
Methods
This study was conducted by the American Association
for Clinical Chemistry (AACC) eGFR and Race
Equity Task Force. The Task Force was composed of
individuals with expertise in clinical laboratory medicine, nephrology, primary care, pharmacy, and/or
evidence-based medicine. Using an evidence-based approach, we performed a systematic review to determine
whether there were data supporting the use of the BRM
in creatinine-based eGFR calculations.
POPULATION/INTERVENTION/COMPARATOR/OUTCOME
PRINCIPLE

The group used the Population/Intervention/
Comparator/Outcome (PICO) principle to frame the
question used for our literature search to capture relevant studies (11). A schematic of the PICO principle applied to our research question is shown in Fig. 1. The
population evaluated included adults in any setting
(inpatient, outpatient, community). The intervention
and associated comparator were defined as creatininebased eGFR equations 6 BRM compared to a direct
measurement of GFR (mGFR) or creatinine clearance.
Comparator equations used to calculate eGFR included
the 4v-MDRD and CKD-EPICr equations, unless otherwise stated. In some cases, the eGFR calculation without the BRM was inferred but was not directly provided
in the publication. Outcomes evaluated included: early
identification of kidney disease; potential delay in progression of renal disease; more rapid decline in kidney
function; morbidity related to kidney disease; drug dose
changes; morbidity not related to underlying kidney disease and cardiovascular events; delay in need for dialysis
or transplant; referral as transplant recipient or donor;
and/or survival.
LITERATURE SEARCH

Our strategy aimed to retrieve a wide range of publications that would provide indirect assessment or linkage
to outcomes because randomized controlled trials or robust comparative studies were unlikely to be available.
Databases were queried in consultation with librarians
at the University of Washington Health Sciences
Library (Seattle, WA). PubMed and Embase Elsevier
databases were searched using medical subject headings
(MeSH) terms and keywords in the title or abstract
fields from inception through May 6, 2021, for concepts of kidney function and race. Supplemental File 1
in the online Data Supplement summarizes the search
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height or weight. Rather, both equations estimate
glomerular filtration using an individual’s serum creatinine concentration, age, sex, and a Black race modifier
(BRM). In the original reports describing the development of these equations, incorporation of the BRM
appeared to improve accuracy in the populations evaluated, but specific criteria for when to apply the
BRM was not defined (3, 4). Inclusion of the BRM
results in a 21% and 15.9% higher eGFR at any given
creatinine for the 4v-MDRD and CKD-EPICr equations, respectively. A higher eGFR in a Black person
with the same creatinine concentration as a non-Black
person has the potential to impact multiple facets of
healthcare, including transplant donor candidacy,
transplant recipient prioritization, CKD diagnosis,
and drug administration (5).
In laboratory medicine, extensive quality control
and quality assurance measures are taken to ensure accuracy and precision, particularly for analytes in which
clinical decision points are based. The advent of estimating equations to assess filtration rates prompted such
standardization for creatinine measurements. For example, there have been important efforts in establishing
standardized creatinine measurements to ensure that the
bias between laboratories is minimized (6, 7). By analogy, there is no method to standardize the application
of race. Race is a social construct and not a binary term
that can be defined by specific demographic or genetic markers (8). Race is inconsistently inferred
based on skin color or assessed by self-identification,
and is often poorly described in literature, including
in studies that use race as a covariate. The potential
heterogeneity in the assignment and interpretation of
race compromises the applicability of the BRM in
eGFR calculations. There are few instances in medicine where visual assessments are appropriate standards. Thus, allowing for bias in estimates based on
race influences laboratory result interpretation and
downstream clinical care.
The use of the BRM in eGFR calculations has been
heavily debated (9). Many clinicians support the removal of the BRM from the MDRD and CKD-EPICr
calculations, but there has been limited concrete evidence to support a broad scale movement to change
this practice. Recently, newly derived equations, which
use age, sex, and serum creatinine only, have been
published in hopes of reducing racial bias in eGFR
assessment (10). Our purpose here was to further
examine the use of the BRM as classically applied by
an evidence-based approach to systematically assess
the medical literature. The application of the BRM in
the MDRD and CKD-EPICr eGFR equations was
questioned and the downstream clinical impact of the
use or removal of the BRM was assessed. Our ultimate goal was to assimilate the available literature to
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terms used. Identified studies were collated as an .xml
file and uploaded into the CovidenceTM systematic review management software program (Melbourne,
Australia). Studies were screened for duplications, and
nonduplicated publications were extracted as an .xml
file and uploaded into Covidence. Literature screening
and review steps were conducted in Covidence.
ELIGIBILITY SCREENING

Publications were eligible if they reported on studies that
had assessed the following in a racially diverse adult cohort:
compared eGFR with the inclusion and/or exclusion of
the BRM to gold-standard mGFR methods (51Cr-EDTA,
99m
TC-DTPA, or iohexol clearance); eGFR comparisons
with and without the BRM; or linkage of eGFR with or
without the BRM to clinical outcomes. Studies were ineligible if race was used exclusively as a risk factor; if CKD
reclassification was evaluated without assessing exclusion of
the BRM (e.g., MDRD with BRM to CKD-EPICr with
BRM); if there was insufficient data to perform an informed comparison.
Studies were excluded based on one of the following criteria: publication in a non-English language; use
of an Asian-specific eGFR equation; opinion piece/review; case report; incorrect analyte (e.g., focus on urine
albumin, cystatin C); non-4v-MDRD or non-CKDEPICr equation/comparator; population <18 years of
age; or selective population (e.g., race was not specified;
individuals with acute kidney injury).

Each publication’s title and abstract were screened
by 2 individuals to determine if the published content
contained information that evaluated the use of the
BRM in commonly used eGFR equations, and scored as
“yes,” “no,” or “maybe.” Publications screened “yes” by
both reviewers were selected for a full-text review; publications screened “no” by both reviewers were excluded
from further analysis; abstracts assigned as “maybe” by
either reviewer and abstracts with discordant reviews
were adjudicated by a third member or subjected to a
group discussion.
Full-text reviews were performed independently by
2 individuals to further evaluate whether the publication
was relevant to the research question; included studies
were then subjected to qualitative data extraction. If a
study was excluded for more than one reason, the highest ranked exclusionary criterion was selected in
Covidence. Discordant assessments were adjudicated by
a subset of Task Force members with specific expertise
in kidney care and/or laboratory medicine.
DATA EXTRACTION

Data from included studies were extracted using wordbased extraction templates (Supplemental File 2). Key
parameters captured included: demographic information
(including the reported race of participants), study
design and setting, analytical methods and eGFR equations, interventions conducted, and outcomes assessed.
During data extraction, reviewers were allowed to
Clinical Chemistry 00:0 (2022) 3
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Fig. 1. Schematic of the population/intervention/comparator/outcome principle used to assess the utility of using the BRM in
eGFR equations.
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DATA CATEGORIZATION

Included studies were divided into 2 main categories,
those that assessed whether the BRM improved the accuracy of the eGFR and those that explored outcomes
related to the use of the BRM. The majority of studies
in the former group were performed in African settings;
however, we also identified several reports from Brazil.
Studies in the outcomes category were stratified as
follows: metabolic derangements and renal outcomes;
kidney transplant donors; medication dosing; and
changes in CKD categorization.
METHODOLOGICAL QUALITY ASSESSMENT

To identify potential deficiencies in included studies,
the team assessed overall methodological quality. Given
the variety of study designs that were anticipated, we
chose to evaluate quality as pertaining to the review
questions rather than to use a single instrument or assessment tool. Our evaluation of methodologic quality
was informed by, but not limited to, the following features: quality of study population; quality of the study
design; analytical methods used, including assessment of
creatinine methodology and isotope dilution mass spectrometry traceability; and author interpretation. We
prospectively identified areas of particular concern as the
following: repeated use of the same population; small
number of Black participants; repeated conclusions by
same authorship; use of nonstandardized creatinine
measurements; and/or deficiencies in data analysis.
REGISTRATION

This study was registered with the Open Source
Framework (Number 10.17605/OSF.IO/59X86).
Results
IDENTIFICATION OF PUBLICATIONS FOR DATA EXTRACTION

Using defined MeSH terms, 8632 unique publications
were identified (Fig. 2). Of these, 413 full-text publications were assessed for eligibility and 320 were excluded.
Studies were most commonly classified as ineligible due
to insufficient data for comparing eGFR results (27%)
and using an incorrect study design, such as the use of
Black race as a risk factor for kidney disease (20%).
Studies were most commonly excluded due to use of
Asian-specific eGFR equations (10%). After exclusion
4 Clinical Chemistry 00:0 (2022)

and initial eligibility assessments, 93 studies (1.08% of
all studies screened) remained for analysis and data
extraction. After evaluation of study references and augmented review of literature databases, an additional 3
studies were identified, resulting in a total of 96 studies
for further analysis.
Of the 96 studies, 12 focused on Indigenous populations from Australia or the USA and did not use
the BRM; 30 studies considered the performance of the
BRM in African and Brazilian populations and 54 explored the accuracy of the equations and the impact of
the equations on outcome. These 84 included studies
were subjected to data extraction using a standardized
template (Supplemental File 2). Overall, we noted that
race was inadequately defined or described in many
of the studies included in our analysis.
COMPARISON OF eGFR CALCULATIONS TO mGFR IN AFRICAN/
BRAZILIAN POPULATIONS

There were 30 studies conducted in African and
Brazilian settings, including 27 cross-sectional studies, 2
longitudinal studies, and 1 commentary (Fig. 3). One
study was excluded post hoc because it was a commentary, and 1 cross-sectional study was excluded because it
was an abstract. Methodologic shortcomings were noted
in 8 of 28 (29%) of eligible African/Brazilian studies;
these deficiencies may compromise the validity of the
findings. The most common shortcomings included
over-interpretation of study findings; deficiencies
in study design; and inadequate description of the criteria for assigning race in the study group evaluated.
However, none of these were identified in studies in
which there was a direct comparison between eGFR
calculations and mGFR.
Ten cross-sectional studies compared mGFR via
51
Cr-EDTA, 99mTC-DTPA, or iohexol clearance with
the 4v-MDRD or CKD-EPICr eGFR equations in the
presence or absence of the BRM (Table 1) (12–21).
Across these studies, data from 1749 individuals were
evaluated; settings were enriched for Black African,
Brazilian, or admixed populations. Healthy persons,
persons living with human immunodeficiency virus
(HIV) and naı̈ve to antiretroviral therapy, and individuals with CKD were all represented in these studies. We
extracted comparison data from the 10 studies to identify the estimation calculation that provided the closest
overall agreement with mGFR. In all studies, calculations without the BRM showed closer agreement with
mGFR results in Black participants. Three of these studies evaluated eGFR using the kidney biomarker cystatin
C; in all of these studies, cystatin C-based equations
showed improved agreement with mGFR when compared to creatinine-only estimations (13, 17, 20).
In Black African populations, generalized conclusions
from these studies recommend exclusion of the BRM in
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further exclude studies if they did not meet the group’s
PICO principle; exclusion of studies at this step was
based on a subgroup discussion and consensus agreement. Further, additional studies were evaluated for
inclusion during this step if they were identified from
references within the primary search literature or were
found in the public domain but had not been retrieved
from the initial query.
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eGFR equations due to poorer agreement with mGFR
results.
Nine of the 28 (32%) studies compared equation
performance to other measures of kidney function,
including 24-hour CrCl, estimated clearance by the
Cockcroft–Gault equation, and urinary albumin to creatinine ratio (Supplemental Table 1). Although 24 h
CrCl and the Cockcroft–Gault clearance overestimate
filtration and are associated with increased scatter, 24 h
CrCl was still viewed as a reference method at the time
many of these studies were conducted (22). Within 7
(78%) of these studies, eGFR equations without the
BRM demonstrated improved agreement with CrCl or
the presence of albuminuria. Two studies presented
mixed results; however, neither study compared eGFR
results to mGFR (8, 9). Omuse and colleagues

supported the use of the CKD-EPICr equation with the
BRM in a non-CKD African population, but acknowledged that additional work was required to determine if
inclusion of the BRM was appropriate as a screening
tool in African community settings (23). Nobrega and
colleagues demonstrated comparable performance of the
4v-MDRD 6 BRM and Cockcroft–Gault equations
with CrCl in an admixed Brazilian population; however,
the authors conceded that, in this population, inclusion
of the BRM may not improve accuracy of filtration
equations and may not be applicable in a Brazilian
population (24).
In the remaining 9 of 28 studies conducted in African
and Brazilian settings, a direct comparison of eGFR 6
BRM was not assessed. However, in 5 of these studies,
eGFR calculations without the BRM were used to evaluate
Clinical Chemistry 00:0 (2022) 5
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Fig. 2. Preferred reporting items for systematic reviews and meta-analyses diagram. Workﬂow for the identiﬁcation of relevant
studies to address the utility of the BRM in eGFR equations.
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kidney function in diverse populations throughout the
Democratic Republic of Congo, South Africa, Uganda,
and Zimbabwe (Supplemental Table 2). Within these
studies, removal of the BRM to estimate GFR was based
on the findings from previous reports, which showed that
BRM inclusion overestimates kidney function in these
populations.
EQUATION COMPARISONS IN NON-AFRICAN/BRAZILIAN
POPULATIONS AND STUDIES LINKED TO OUTCOME

Fifty-four unique studies were identified that compared
eGFR to mGFR outside of African and Brazilian settings or linked the equation to outcome (Fig. 4). Of
these, 51 were identified from the forward search; 3
were identified using a reverse approach whereby the
committee extracted the text of select references within
the included studies. On further review, 38 studies were
excluded due to: using Black race exclusively as a risk
factor (wrong comparator; n ¼ 7), wrong publication
type (commentary, abstract only, review n ¼ 8), wrong
study design (no BRM assessment; n ¼ 13), or wrong
intervention (comparison of only BRM-inclusive equations; n ¼ 10) (Supplemental Table 3). Most of the included studies were cross-sectional (n ¼ 12) (25–36), 3
were longitudinal (37–39), and 1 was both cross-sectional and longitudinal (40). Fifteen of the 16 included
studies featured North American populations; 1 report
(28) was conducted in the UK.
The 16 included studies fell into 4 broad categories: those that examined metabolic or kidney endpoints in the context of the eGFR (n ¼ 4), those
6 Clinical Chemistry 00:0 (2022)

evaluating kidney donors (n ¼ 4), and those which
recalculated eGFR with and without the BRM to
identify the number of individuals who would be affected at clinically meaningful thresholds of care due
to medication dosing (n ¼ 2) or changes in CKD categorization (n ¼ 6) (Table 2). Overall, the most consistent quality deficiency of the included studies was
that most were unable to document actual outcomes
related to the potential CKD reclassification (4 of 6
studies) or clinical impact of medication changes (2 of
2 studies). This is a general limitation of cross-sectional and/or retrospective studies and prohibited definitive conclusions regarding kidney function and
appropriate management with or without the BRM.
An additional bias was seen in sampling from the
same population. Levey et al. demonstrated that
mGFR most closely correlated to eGFR calculated
with the BRM, but this cohort was identical to that
used to derive the equation, limiting its broader applicability (34).
METABOLIC DERANGEMENTS AND KIDNEY OUTCOMES

Metabolic parameters or kidney endpoints were assessed
in 4 studies. de Boer et al. examined patients at different
levels of kidney function, categorized by eGFR, and
found that compared to White participants, Black participants had more secondary hyperparathyroidism at
higher eGFRs using the BRM (25). Similarly, Ibrahim
found that Black participants with eGFR <60 mL min1
(1.73 m2)-1 using the BRM more frequently presented
with anemia, hyperuricemia, and hyperparathyroidism

Downloaded from https://academic.oup.com/clinchem/advance-article/doi/10.1093/clinchem/hvab279/6470563 by Henry Ford Hospital user on 15 February 2022

Fig. 3. Categorization of African/Brazilian studies identiﬁed for data extraction and evaluation. *One study was excluded because it was an abstract.
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Table 1. Comparison of eGFR calculations to mGFR in African/Brazilian populations.

Year

Country

N

%
Black

Population
enriched

Equations

mGFR method

Van Deventer
et al (12)

2008 South Africa

100

100

Hypertension;
T2DM; HIVþ

C-G; 4v-MDRD

51

Van Deventer
et al. (13)

2011 South Africa

100

100

Hypertension;
T2DM; HIVþ

CKD-EPIcra; 4vMDRDa; novel Cr
and Cys
equations

51

Madala et al.
(14)

2012 South Africa

148

62

CKD

C-G; 4v-MDRD

99m

4v-MDRD without
BRM

Zanocco et al.
(15)

2012 Brazil

244

8

CKD

C-G; CKD-EPICr; 4vMDRD; Mayo
Clinic; Brazil
eGFR

iohexol clearance

CKD-EPICr without
BRM

Wyatt et al.
(16)

2013 Kenya

99

NS

HIVþ/ART-naı̈ve

C-G; CKD-EPICr; 4vMDRD

iohexol
clearance

CKD-EPICr without
BRM

Seape et al.
(17)

2015 South Africa

97

100

HIVþ/ART-naı̈ve

C-G; CKD-EPICr;
CKD-EPIcys; CKDEPICr-cys; 4vMDRD; novel SCys-C equation

51

CKD-EPICr-cys without BRM

Moodley et al.
(18)

2018 South Africa

287

66

Malignancy;
Hypertension;
T2DM; HIVþ

CKD-EPICr; 4vMDRD

99m

Tc-DTPA
clearance

CKD-EPICr without
BRM

Bukabau et al.
(19)

2019 Democratic
Republic of
CongoCôte
d’Ivoire

494

NS

None; community

CKD-EPICr; 4vMDRD; FAS

iohexol
clearance

CKD-EPICr without
BRM

Rocha et al.
(20)

2020 Brazil

100

61b

CKD

CKD-EPICr; CKDEPICr-cys

51

CKD-EPICr-cys without BRM

Holness et al.
(21)

2020 South Africa

80

NSc

CKD

CKD-EPIcr; 4vMDRD

99m

Cr-EDTA
clearance
Cr-EDTA
clearance

Tc-DTPA
clearance

Cr-EDTA
clearance

Cr-EDTA
clearance
Tc-DTPA
clearance

4v-MDRD without
BRM
Novel equations
with cys; CKDEPICr
without BRM

CKD-EPIcr without
BRM

Abbreviations: 4v-MDRD: 4 variable Modiﬁcation of Diet in Renal Disease; ART: antiretroviral therapy; BRM: Black race modiﬁer; C-G: Cockroft-Gault; CKD: chronic kidney disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; Cr: creatinine; cys: cystatin C; DTPA: Diethylenetriamine pentaacetate; EDTA: Ethylenediaminetetraacetic
acid; HIV: human immunodeﬁciency virus; mGFR: measured glomerular ﬁltration rate; T2DM: type 2 diabetes mellitus.
a
BRM not used for eGFR calculations.
b
African-Brazilian; admixed population.
c
All participants self-identiﬁed as mixed ancestry.

(26). Peralta et al. documented that Black men with an
eGFR of 60–80 mL min-1 (1.73 m2)-1 had a 2.5-fold
higher prevalence of albuminuria and hyperuricemia
when compared to White participants with similar kidney function (27). Last, Mahmud et al. evaluated baseline eGFR in cirrhotic patients with and without the use
of the BRM, finding that removal of the BRM increased
the association between lower eGFR and higher rates of
acute kidney injury (AKI) (37). In these 4 studies, use
of the eGFR with the BRM resulted in discordance with
other markers of kidney disease in Black patients.
KIDNEY TRANSPLANT DONORS

Evaluation of potential kidney donors using the eGFR
with BRM was assessed in 3 studies (28–30). By

comparing mGFR to eGFR, all 3 concluded that the
eGFR overestimated the mGFR in Black donor candidates and that use of the BRM had the potential to allow kidney donation by candidates who should be
rejected for reduced kidney function. One of these studies was conducted in the UK and the authors postulated
that the BRM might not be applicable outside North
America. Decline in kidney function based on the
eGFR in living kidney donors was assessed in a single
study where the investigators compared eGFR in White
and Black patients before and after kidney donation and
found that Black donors had a more significant decline
in eGFR after donation, suggesting that inclusion of the
BRM in eGFR calculations may overestimate kidney
function in Black kidney donors (38).
Clinical Chemistry 00:0 (2022) 7

Downloaded from https://academic.oup.com/clinchem/advance-article/doi/10.1093/clinchem/hvab279/6470563 by Henry Ford Hospital user on 15 February 2022

Author
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agreement
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MEDICATION DOSING

The influence of the BRM in medication dosing was
evaluated in 2 studies. Miller and Knorr compared
CKD-EPICr with and without the BRM deindexed for
body surface area and concluded that the exclusion of
the BRM correlated more closely with estimated CrCl
from the Cockcroft–Gault equation, which was used to
establish most dosing guidelines (31). The second study
recalculated eGFR in patients from the NHANES database with type 2 diabetes mellitus to determine how
many patients would no longer be eligible for metformin or sodium-glucose transporter type 2 (SGLT2)
inhibitors after removal of the BRM. These studies were
not designed to confirm which medication dosing was
most clinically appropriate, only that use of the BRM
would change prescribing patterns in a subset of Black
individuals (32).
CHANGE IN CKD CATEGORIZATION

Four studies retrospectively re-examined datasets to evaluate the effects of excluding the BRM from eGFR calculations. In these mathematical exercises, removal of the
BRM for Black patients reclassified many individuals to
a more severe stage of CKD. Ahmed et al. found that
33.4% of patients with established CKD at a large metropolitan hospital system would be reclassified to a later
stage of CKD and 3.1% would achieve a qualifying
eGFR to be eligible for kidney transplantation listing
(40). Diao et al. found that 29.1% of NHANES participants with established CKD based on eGFR with the
BRM would be reclassified as having a more severe stage
of CKD in the absence of the BRM. In addition, they
reported that the number of Black persons with CKD
stage 4 would increase from 1.0% to 1.3% with removal
8 Clinical Chemistry 00:0 (2022)

of the BRM (35). Ku et al. examined transplant eligibility for Chronic Renal Insufficiency Cohort participants
and found that removal of the BRM reduced the disparity between Black and White participants (36). The
results also documented an attenuated difference in proteinuria between Black and White participants when the
BRM was removed. In a cohort of HIV positive persons, Anker et al. calculated that removal of the BRM
improved the association between eGFR and all-cause
mortality (39).
Two studies looked at the performance of eGFR
calculations as a function of the bias between mGFR
and eGFR. One of these compared mGFR to eGFR 6
BRM using data from the Black patients included in the
CKD-EPI development cohorts. The authors concluded
that eGFR with the BRM improved the association
with mGFR (34). The second study observed that, relative to mGFR, eGFR calculated with the BRM for
Black women had the most bias compared to Black men
and White men or women, although minimal bias between demographic categories was observed for eGFR
values <60 mL min-1 (1.73 m2)-1 (33).
Discussion
Using a PICO-guided, evidence-based approach, we observed that there is little published evidence to support
the inclusion of the BRM in commonly utilized eGFR
equations. Only 1 of the identified studies demonstrated
that the modifier improved estimation accuracy on a
population level and suggested clinical benefits in Black
populations. However, this report used the study group
from which the CKD-EPICr equation was derived (34).
Overall, the use of the BRM in the 4v-MDRD and
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Fig. 4. Categorization of outcome studies identiﬁed for data extraction and evaluation.
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Author

Population
assessed

Year

N

%
Black

Outcome
evaluated

eGFR
equations
used

mGFR

eGFR
assessed
6BRM

A. Metabolic derangements and kidney outcomes
De Boer et al.
(25)

2002

CKD clinic

218

22

Metabolic
derangements

4v-MDRD

no

no

Ibrahim et al.
(26)

2008

NHANES
participants

8918

11

Metabolic
derangements

4v-MDRD

no

no

Peralta et al.
(27)

2010

CARDIA
participants

3504

47

CKD, metabolic
derangements,
albuminuria

4v-MDRD; CKDEPICr; CARDIA

no

no

Mahmud et al.
(37)

2021

19.7

AKI risk

4v-MDRD; CKD-EPICr

no

yes

cirrhotic patients

72 267

B. Kidney transplant donors
Parasuraman
et al. (38)

2008

Kidney donors

103

52

Decline in eGFR after
donation

4v-MDRD

no

no

Bhuvanakrishna et al. (28,
*

2015

potential kidney
donors

508

11.8

Donor candidacy vs
51
Cr-EDTA clearance

CG; 4v-MDRD;
CKD-EPICr

yes

no

Akhimiona
et al. (29)

2018

potential kidney
donors

210

11.4

Donor candidacy vs I125labeled iothalamate
clearance

CKD-EPICr

yes

yes

Garg et al. (30)

2019

potential kidney
donors

769

10.4

Donor candidacy vs I125labeled iothalamate
clearance

CKD-EPICr; CrCl;
CER2, CER4

yes

no

hospitalized
patients

210

84

Antibiotic dosing
discordance

CG; CKD-EPICr–deindexed for BSA

no

yes

923

100

Change CKD category;
eligibility for T2DM
medications

CKD-EPICr

no

yes

21 905

55

Change in CKD category; mortality

4v-MDRD; CKD-EPICr

no

yes

294

47

Equations vs iohexol
clearance

CKD-EPICr;
CKD-EPIcys;
CKD-EPICr-cys

yes

no

Change in CKD category; transplant
eligibility

CKD-EPICr

no

yes

C. Medication dosing
Miller et al.
(31)

2021

Walther et al.
(32)

2021

NHANES
participants

D. Change in CKD categorization
Anker et al.
(39)

2016

HIV veterans

Inker et al. (33)

2018

MESA participants

Ahmed et al.
(40)

2020

outpatients at 2
tertiary care
centers

Levey et al.
(34)

2020

CKD-EPI
population

2601

100

Equation performance

CKD-EPICr

no

yes

Diao et al. (35)

2021

NHANES
participants

9522

100

Change in CKD category; transplant
eligibility

CKD-EPICr

no

yes

Ku et al. (36)

2021

444

65

Transplant eligibility

CKD-EPICr;
CKD-EPIcys;
CKD-EPICr-cys

no

yes

CRIC participants

56 845

3.9

Abbreviations: 4v-MDRD: 4 variable Modiﬁcation of Diet in Renal Disease; BRM: Black race modiﬁer; BSA: body surface area; AKI: acute kidney injury; CER: creatinine excretion
rate; CARDIA: Coronary Artery Risk Development in Young Adults; C-G: Cockroft-Gault; CKD: chronic kidney disease; CKD-EPI: Chronic Kidney Disease Epidemiology
Collaboration; Cr: creatinine; cys: cystatin C; CrCl: creatinine clearance; CRIC: Chronic Renal Insufﬁciency Cohort; EDTA: Ethylenediaminetetraacetic acid, HIV: human immunodeﬁciency virus; MESA: Multiethnic Study of Atherosclerosis; mGFR: measured glomerular ﬁltration rate; NHANES: National Health and Nutrition Examination Survey; T2DM:
type 2 diabetes mellitus.
*Conducted in the UK.
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Table 2. Comparison of eGFR calculations to mGFR in non-African/Brazilian populations; Linkage of eGFR to clinical
outcomes.

Review
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those who self-reported as Hispanic/Latino Americans
were 28.6% African with a range of 0%–100% (45).
These discrepancies underscore the challenges of using
an imprecise and often subjective term in estimation
equations in the categorization of kidney function.
Our systematic review identified a limited number of
studies that linked the use of the BRM in estimated GFR
calculations to outcomes. Several studies identified more
metabolic consequences of CKD in Black individuals with
higher eGFRs. Instead of questioning whether BRM inclusion may overestimate kidney function, the authors postulated that there may be additional innate differences in
metabolism of urate or race-specific differences in parathyroid hormone dynamics to explain these findings (25, 26).
These studies did not assess if removal of the BRM would
minimize the observed disparities, but, taken together,
these outcomes suggest that the use of the BRM in the
eGFR may overestimate kidney function.
Removal of the BRM will predictably result in a lower
eGFR for Black participants compared to the estimate
when the BRM is applied. In the cohort of Black patients
used to develop the CKD-EPICr equation with the BRM,
this leads to an apparent underestimate of kidney function,
which was the foundation for including the modifier in
clinical practice recommendations (34). Proponents of the
equations with the BRM suggest simply removing the
BRM will result in a range of adverse consequences, including exclusion of potential kidney donors. We identified 3 studies that addressed donor evaluation, and all
found that BRM inclusion overestimated potential donor
kidney function in Black participants. Thus, removal of
the BRM may protect potential donors from harm rather
than limit donation by a healthy donor. Further, we identified one report that found a greater decline in eGFR after
donation for Black donors. The authors postulated that
calculated eGFR overestimated kidney function in Black
donors or that Black donors might have less functional reserve than White donors (38).
The BRM also has important implications for the potential kidney transplant recipient. Since the eGFR equations result in higher estimates of kidney function at any
given creatinine for Black patients, Black patients must
have a higher creatinine than White patients to achieve a
qualifying eGFR for kidney transplant eligibility. Removal
of the BRM has the potential to allow Black patients to be
listed for kidney transplant with the same criteria as nonBlack patients; several studies calculated the number of
individuals who would benefit from such a change (35, 36,
40). Recently, this benefit was demonstrated at one institution in a small number of patients who achieved a qualifying eGFR without the BRM and were listed for
preemptive transplant, on average, 1 year earlier than if the
eGFR was calculated with the BRM (46).
Removal of the BRM would assign a more severe
CKD stage for a percentage of patients whose kidney
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CKD-EPICr equations showed lower concordance with
gold-standard measures of GFR; this was highly evident
across Black African cohorts. Further, our findings demonstrate that there is insufficient data to illustrate a benefit of using the BRM in supporting clinical outcomes.
We identified several critically relevant studies conducted in Black African populations that directly assessed
the applicability of the BRM in eGFR equations. When
compared to iohexol, 99mTc-DTPA, or 51Cr EDTA clearance assessments, it was consistently observed that the use
of the BRM resulted in increased bias and decreased precision and accuracy of filtration rate estimates (12, 16, 18,
21). For example, in an admixed African population
enriched for CKD, the percentage of patients whose eGFR
was within 630% of 99mTc-DTPA clearance (P30) decreased from 80% to 51% when the BRM was applied to
the 4v-MDRD equation; similar observations were made
when the CKD-EPICr equation was used (21). Bukabau
and colleagues concluded that the BRM was not accurate
in healthy or diseased African populations, and that BRMinclusive eGFR bias and imprecision were exacerbated in
healthy populations (19). The authors further suggested
that the lack of transferability of the BRM to African populations may be attributable to differences in muscle mass
or diet between sub-Saharan African participants and
African-Americans. However, the use of muscle mass or
body weight as stratifying features has also been called into
question (41). The finding that the BRM does not improve eGFR accuracy in African populations is not a new
observation; however, this is the first time that these studies have been combined in a systematic review that
includes data on 1749 Black individuals, nearly 10 times
the number of Black individuals in the MDRD study and
comparable to the number of Black individuals in the development set of the CKD-EPICr equation (3, 4).
Although the use of BRM-inclusive eGFR equations is commonplace in the USA and Canada, the
BRM is frequently not used when estimating GFR in
African settings. During our review of studies, we also
noted similar approaches in Asian-enriched populations;
many eGFR equations have been developed in Asian
populations, which include population-specific modifiers or employ alternative equations to estimate GFR
(42). Importantly, none of the race modifiers for eGFR
equations consider how to define race or whether to
equate it with ancestry; none account for individuals of
mixed race, what proportion of ancestry is required for
use of a race modifier, and how to apply the coefficient
if ancestry differs from how an individual self-identifies
(43). Use of binary coding to reflect ethnic and ancestral
backgrounds oversimplifies the genetic diversity of the
population and is error prone (44). Indeed, in a study
comparing self-reported ancestry to genetic background,
those who self-reported as African American were on average 82% African but the range was 0.6%–100% and
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Foundation (NKF) and American Society of Nephrology
(ASN) established a joint task force to examine the social
and clinical implications of including the BRM in eGFR
equations, as well as identifying approaches to GFR estimating equations that are unbiased and promote healthcare
equity. An interim report published in June 2021 outlined
the steps taken to reach consensus (9). The NKF/ASN
Task Force subsequently published a unifying report and a
new equation (10, 58). The equation is designed to reduce
bias in eGFR and offer a standardized approach for implementation. Further, the new equation removes the necessity to identify people by race, which aligns with the data
collated in this systematic review. Our Task Force endorses
this unifying approach to eGFR reporting, which reinforces
the steps that laboratories take for precision in creatinine
measurements and their postanalytical interpretation.
As evidenced by this work, there is an absence of
substantial data demonstrating analytical or clinical benefit to the use of the BRM in eGFR equations. Further,
these results illustrate that an estimated filtration rate is
still an estimate, and when values are close to a clinically
significant cut off, it should not be used independent of
other factors. Other biomarkers of kidney dysfunction,
including serum/plasma cystatin C and the urine albumin/creatinine ratio, can also provide useful information
on filtration rate and future risk of kidney failure, respectively (59, 60). Although studies focused solely on
cystatin C as a renal biomarker were not part of our eligibility criteria, several eligible studies compared
creatinine-based eGFR equations with estimation equations containing cystatin C. Notably, estimation equations that only use cystatin C as the kidney biomarker
do not require a race modifier, suggesting potential expansion and adoption of cystatin C as a preferred kidney
biomarker, particularly in highly admixed or diverse
populations (61). The NKF/ASN Task Force has also
incorporated cystatin C into their recommendations, deriving a new equation that uses cystatin C and creatinine. This equation is free of racial modifiers and more
accurately classifies patients relative to the creatinineonly equations in estimating GFR (10, 58).
Although our findings are consistent with previous
evaluations, there are limitations in our methodologic
approach. In this systematic review, we noted heterogeneity in the types of studies available in publicly available databases; there was an overall paucity in the
number of studies that performed direct equation comparisons in the presence of absence of the BRM or used
a randomized design. Consequently, we did not expect
to observe substantial direct evidence demonstrating the
health effects of the BRM for Black populations; rather,
we relied on indirect evidence, including the linkage of
eGFR in the presence and/or absence of the BRM to
clinical outcomes. Further, given the variety of study
designs encountered in our investigation, we were
Clinical Chemistry 00:0 (2022) 11
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function is close to clinically significant thresholds for
care. This may result in a new diagnosis of CKD that
should prompt simple measures such as an increased attention to blood pressure and measurement of urinary
albumin or additional assessment of kidney function to
confirm the diagnosis in the spirit of shared decisionmaking between patients and providers (47).
Reclassification of CKD staging can also impact
pharmacologic dosing. This is of particular concern for
patients with reduced kidney function who have type 2
diabetes mellitus, as both metformin and SGLT2 inhibitors are not recommended below eGFR of 30 mL min1
(1.73 m2)-1 (32). We found only 1 report that examined
this issue but it was based on hypothetical changes in renal
function rather than clinical practice (32). Recently, this
topic was examined in a sample of cancer patients for dosing chemotherapeutic agents that are renally cleared. In
this simulation, 1%–18% of patients would have required
a reduction in therapeutic dosing. Since eGFR is a calculated estimate, and chemotherapeutic agents are associated
with significant potential toxicity, careful assessment of kidney function is required (48).
Adoption of eGFR equations prompted a movement to streamline the terminology used to describe
kidney function and standardization of creatinine measurement. These efforts also led to the adoption of a
more comprehensive and collaborative federal response
to CKD (49). Yet the use of BRM-inclusive calculations, which result in better kidney function for Black
patients at every creatinine concentration, can lead to
harm. Since race is a social construct and cannot be precisely defined or implemented, the use of race-specific
modifiers in healthcare can contribute to significant disparities in clinical diagnoses, access to care, and clinical interventions (50–53). The inclusion of race in eGFR
equations inherently engenders bias and promotes mistrust
between marginalized patient populations and the healthcare system. Social justice reforms in the medical community are needed to achieve healthcare equity (54).
The findings from this work align with current position statements and commentaries calling for the removal of the BRM in eGFR equations (5, 55–57).
Several institutions have already initiated changes to
eGFR reporting practices (50). Deployed modifications
include removal of the BRM from the 4v-MDRD or
CKD-EPICr equations and reporting a single eGFR result per creatinine measurement; the re-expression of
race as low or high muscle mass; reporting eGFR as a
range; or the inclusion of an interpretive comment to
provide clinical decision support on the appropriate interpretation of eGFR values. While there is merit to
each of these approaches, caution is also needed, as increased variability can lead to further destandardization
of eGFR reporting, leading to unintended consequences
on clinical care. In 2020, the National Kidney
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